Groundbreaking Therapy for Advanced Heart Failure: Repairon Completes Series A Financing to Expand the Clinical Development of Its Regenerative Heart Therapy

GÖTTINGEN, Germany, Oct. 2, 2025 /PRNewswire/ -- German biotech company Repairon GmbH announced the completion of a Series A round of financing that will enable further clinical development of its groundbreaking regenerative heart failure therapy. The therapy repairs cardiac function and holds the potential to significantly improve quality of life in patients with advanced heart failure by engrafting lab-engineered cardiac cell sheets to the surface of a damaged ventricle. This approach is currently being tested in a Phase 1/2 clinical study in Germany. Recruitment for the interim analysis of the Phase 2 was completed recently. Preclinical outcomes were published in the journal Nature earlier this year.

Led by Bioventure Management GmbH and strategic co-investor Satorius AG, the financing will enable the transition to a European Phase 3 registration trial and the scaling of GMP (Good Manufacturing Practice) production in collaboration and with know-how from Satorius AG. Erik Hoppe, Ph.D., Managing Director of Bioventure, said: "Repairon stands for visionary research with social relevance. The company has the potential to fundamentally change the treatment of heart failure." Lothar Germeroth, Ph.D., CEO of Repairon, added that "the engineered heart muscle offers the prospect of reversing the course of congestive heart failure and significantly improving quality of life. For the first time, we see the opportunity to treat a previously incurable and expensive disease causally – with real global benefits for both patients and healthcare systems."

The approach to repair damaged heart muscle with lab-produced heart tissue sheets is based on more than 30 years of research led by Wolfram-Hubertus Zimmermann, MD, Ph.D., professor and director of the Institute of Pharmacology and Toxicology at the University Medical Center Goettingen (UMG) in Northern Germany. Repairon, UMG, and the German Center of Cardiovascular Research (DZHK) collaborate closely on the development of this technology.

High medical need in advanced heart failure:  Approximately 5% of the population in Germany suffers from chronic heart failure of any severity, and it is the third most common cause of death in this country. In the US, heart failure represents the most common cause of hospitalization and mortality in the senior population, and over 6 million people are affected. As the heart failure progresses to advanced stages, patients experience weakness with discomfort during all physical activities and at rest, sometimes even requiring constant bed rest. For these severely ill patients, the only treatment options currently available are mechanical pump devices or heart transplantation.

About Repairon:  Repairon GmbH is a German biotech company based in Göttingen, Germany, focused on developing regenerative cell therapies for cardiac medicine. The company was founded in 2014 based on research by Wolfram-Hubertus Zimmermann, MD, Ph.D. and his team at the University Medical Center Goettingen, who have developed several tissue engineering technologies with proven applicability for organ repair and drug development. Repairon's lead therapeutic candidate, the human engineered heart muscle sheet, is currently being evaluated in the BioVAT-HF Phase 2 clinical trial as a biological ventricular support tissue for end-stage heart failure.

About Bioventure:  Founded in 2001, Bioventure has evolved from a specialized consulting firm into a successful investor in life science companies. Its focus is on companies with the potential to achieve measurable improvements in healthcare through biomedical innovations. Its investment model is based on exclusive financing vehicles (club deals), allowing wealthy entrepreneurial families and family offices to participate in promising individual projects. Bioventure's active support – from selection and strategic development to exit – has led to the distribution of more than €100 million to investors. Successful exits with company valuations in the hundreds of millions to billions of euros underscore Bioventure's expertise in scaling high-growth startups.

SOURCE Repairon GmbH